Jaguar Health, Inc. (JAGX)

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi

Jaguar Health Announces a Special Stock Dividend

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float

Jaguar Health Stock Surges Friday: What's Happening?

Jaguar Health Stock Slides Thursday: What's Happening?

Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%

Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%

Jaguar Health Stock Plunges Wednesday: What's Happening?

Jaguar Health Receives Fee Waivers from FDA

Jaguar Health, Inc. Announces Reverse Stock Split

Jaguar Health Stock Slides Thursday: What's Happening?

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript

Jaguar Health Reports Second Quarter 2026 Financials

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

Jaguar Animal Health (NASDAQ:JAGX) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1